![facebook beta bionics facebook beta bionics](https://i.ebayimg.com/images/g/eD8AAOSwDs9dnh~w/s-l400.jpg)
But even 10 percent of the type 2 population in the US - and I believe in Europe as well - is more than the number of people with type 1 diabetes in the US. “Maybe 10 percent of the type 2 population is on insulin therapy, maybe more. The device could thus be used by anyone with that disease.īut according to the CEO, it could also benefit an even greater number of people with type 2 diabetes. The device, known as the iLet, could become the world’s first fully automated artificial pancreas system, meant to deliver the two hormones insulin and glucagon that people with type 1 diabetes are unable to produce naturally. And the company could be ready to launch the product on the first markets in a matter of years, founder and CEO, Ed Damiano, says in an interview with MedWatch. For further information, please visit or follow Beta Bionics Facebook, YouTube, Instagram, LinkedIn and Twitter source version on businesswire.Nearly 80 million diabetics worldwide could potentially benefit from a new medical device being developed by the US-based medtech company Beta Bionics. Beta Bionics is pursuing regulatory clearance of its insulin-only bionic pancreas, followed by its dual-hormone system, which will also administer a glucagon analog in order to raise blood-sugar levels without the need to consume carbohydrates.īeta Bionics operates in Massachusetts and California. Beta Bionics is committed to acting in the best interests of the diabetes community and to bringing the iLet to market as expeditiously and responsibly as possible. Beta Bionics is a Certified B Corporation™ whose founders - in addition to Ed Damiano - include other parents of children with T1D and people with T1D. These mathematical dosing algorithms were developed in the Damiano Lab at Boston University and refined based on results from home-use clinical trials in adults and children with T1D. The iLet controls glycemia using integrated mathematical dosing algorithms, which incorporate lifelong autonomous learning to determine and automatically deliver microdoses of insulin and glucagon. Ed Damiano, President and CEO of Beta Bionics.īeta Bionics ® is a for-profit Massachusetts public benefit corporation founded in 2015 to commercialize the iLet bionic pancreas system. Jeff Hitchcock from Children With Diabetes, and Dr. Finny Kuruvilla from Eventide Asset Management Funds, Mr. Brooke will be serving as Director alongside Ms. I am also excited to do this as a Certified B corporation and have the opportunity to govern in accordance with the company’s incredible mission," said Ms. "I’m honored to have the opportunity to work with the terrific management team at Beta Bionics to revolutionize the quality of life for so many people dealing with type 1 diabetes and their families. Department of the Treasury and was responsible for tax-policy matters related to healthcare reform, insurance, and managed care. In the Clinton Administration, she worked in the U.S. She is the former Global Vice Chair of Public Policy at Ernst & Young, where she served on its Global Board and as the global sponsor for Diversity and Inclusiveness. Brooke serves on the Boards of eHealth, Inc (NASDAQ:EHTH) and other private companies, in addition to the United States Olympic and Paralympic Committee. This unique experience, combined with her advocacy for diversity and inclusiveness, will be vitally important in guiding our purpose and mission at Beta Bionics, acting in the best possible interest of all people living with type 1 diabetes." "Throughout her career, Beth has helped shape public health policy through her strategic leadership in both the public and private sectors.
![facebook beta bionics facebook beta bionics](https://image.slidesharecdn.com/infographicsplits-02-171216121746/95/beta-bionics-infographic-1-638.jpg)
Her fierce commitment to egalitarianism, opportunity, diversity, and innovation is perfectly aligned with the core principles and values of our benefit mission at Beta Bionics," said Ed Damiano, President and Chief Executive Officer of Beta Bionics. "We are so pleased to have Beth join our Board of Directors at Beta Bionics. a medical technology company developing the iLet ®, the world’s first fully automated bionic pancreas system - today announced that Beth Brooke has been appointed to the Company’s Board of Directors.